

Hong Kong, July 17th 2017

Duotem Capital Limited非常高兴地宣布已成功领导来自中国，香港，新加坡和泰国的投资者一起投资在以色列最有潜能和前途的制药公司之一PolyPid.

这次是这家泰国公司在以色列的首个重大投资，无可否认的是，以色列是现今世界上科技和医疗最创新的国家之一。

PolyPid是一家基于PLEX技术开发和生产产品的专业制药公司。PLEX优化药物的治疗表现和临床结果。

Duotem资本有限公司首席执行官Philippe Metoudi表示："我们非常荣幸能与这些资深与国际化的公司一起进行这一项战略投资。"

PolyPid首席执行官Amir Weisberg表示："我们的公司吸引了来自美国，欧洲，以色列，香港，中国，和通过Duotem Capital Limited现在有泰国和新加坡的投资。我们很期待与Duotem Capital Limited进一步加强我们的合作关系"。

这次PolyPid的投资是Duotem在以色列的第46次交易。

Duotem Capital Limited is pleased to announce a successful investment in one of Israel's most promising pharmaceutical companies, PolyPid. Duotem led a consortium of investors from China, Hong Kong, Singapore and Thailand. Duotem was also one of the investors.

This is the first major investment of a Thai company in Israel, one of the world's most innovative ecosystems.

PolyPid is a specialty pharmaceutical company that develops and manufactures products based on its PLEX technology. PLEX optimises drugs' therapeutic performance and clinical outcomes.

Philippe Metoudi, Chief Executive Officer of Duotem Capital Limited, said, "We are greatly honoured to have collaborated with a highly international group of firms in making this strategic investment."

Amir Weisberg, Chief Executive Officer of PolyPid, said, "Our company has attracted investments from the United States, Europe, Israel, Hong Kong, China, and now Thailand and Singapore .

We are delighted to further enhance our relationship
With Duotem Capital Limited "

This is Duotem's 46th transaction in Israel.